Cardiovascular

Vascepa Brings 36% Drop in Surgeries to Restore Blood Flow, Results Show

July 25, 2020

Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, presented the latest round of data from REDUCE-IT at the American Society of Preventive Cardiology Virtual Summit 2020 this morning

Reduced Risk of Second Stroke With Ticagrelor Plus Aspirin Than Aspirin Alone

July 17, 2020

Transient ischemic attack is a common form of stroke, and 1 in 4 stroke survivors go on to experience a second stroke—most within the first month.

VERTIS CV: Ertugliflozin Falls Short of SGLT2s on CV Outcomes, Despite Promise in Heart Failure

June 16, 2020

A finding that ertugliflozin produced a 30% drop in heart failure hospitalization risk fell outside the study’s primary and secondary end points; here, the drug performed within range of its class, the sodium glucose co-transporter 2 (SGLT2) inhibitors.

Dr Darren K. McGuire Discusses Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in T2D

June 16, 2020

Many in the endocrinology community still endorse using metformin first in patients with type 2 diabetes, but that isn’t really necessary any more now that sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are available, said Darren K. McGuire, MD, MHSc, professor of medicine in the Division of Cardiology, Dallas Heart Ball Chair for Research on Heart Disease in Women, Distinguished Teaching Professor, at the University of Texas Southwestern Medical Center.

Is Prevention the Future of SGLT2s? Inzucchi Offers Data That Suggest "Yes"

June 14, 2020

Yale's Silvio Inzucchi, MD, who has been involved in groundbreaking trials with SGLT2 inhibitors for the past decade, shared data that show patients who did not have type 2 diabetes (T2D) when they started the DAPA-HF trial were 32% less likely to develop the disease if they took dapagliflozin (Farxiga) instead of placebo.

Cardiovascular Benefits of Vascepa Greater for Those With Diabetes, New REDUCE-IT Data Show

June 13, 2020

When it comes to diabetes, lead study author Deepak L. Bhatt, MD, MPH, said clinicians and payers should weigh the considerable costs of what happens when a patient suffers a heart attack or stroke when deciding on a treatment regimen.

Dr Darren K. McGuire Debates SGLT2 Inhibitors and GLP-1 Receptor Agonists as CVD Prime Time Prevention

June 12, 2020

In a debate at the American Diabetes Association 80th Scientific Sessions, Darren K. McGuire, MD, MHSc, professor of medicine in the Division of Cardiology, Dallas Heart Ball Chair for Research on Heart Disease in Women, Distinguished Teaching Professor, at the University of Texas Southwestern Medical Center, will discuss whether sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are ready to be used for primary cardiovascular prevention.

American Heart Association Offers Guidance on Diabetes, Coronary Artery Disease

April 16, 2020

Recently, it has been shown that the mechanism by which glucose is managed can have a substantial impact on cardiovascular outcomes. For this reason, along with increasing prevalence of type 2 diabetes (T2D), effective, patient-centered management of coronary artery disease (CAD) in patients with diabetes is imperative to optimize patient outcomes, the American Heart Association said.

What We're Reading: Coronavirus-Related Heart Issues; Racial Disparities in COVID-19 Outcomes; Urging Smokers to Quit

April 06, 2020

Coronavirus disease 2019 (COVID-19) was linked with cardiovascaluar issues and cardiac arrest; African Americans were shown to have higher rates of infection and death due to COVID-19; health experts call for smokers to cease use and manufacturers to halt production.